StockMarketWire.com - AstraZeneca has announced that Qtrilment has been recommended for marketing authorisation in the EU by the Committe for Medicinal Products for Human Use (CHMP).

The CHMP recommended this for Qtrilmet to improve glycaemic control when metformin with or without SU eor ither saxagliptin or dapagliflozin does not provide adequate glycaemic control, or when or when Type 2 Diabetes patients are already being treated with metformin, saxagliptin and dapagliflozin.

Qtrilmet is is already approved in the US under the name Qternmet XR as an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 Diabetes.



Story provided by StockMarketWire.com